<description>&lt;p&gt;&lt;em&gt;&lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; Neurology Today&lt;/span&gt;&lt;/em&gt; &lt;span style= "font-size: 10.0pt; line-height: 115%; font-family: 'Trebuchet MS',sans-serif; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt; Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on blood pressure targets for stroke after endovascular therapy, changing policies on CME, and a direct-to-consumer blood test for Alzheimer’s disease.&lt;/span&gt;&lt;/p&gt;</description>

Neurology Today in 5

American Academy of Neurology

Blood pressure and endovascular therapy, cutbacks in neurology CME, blood test for Alzheimer’s

OCT 19, 20234 MIN
Neurology Today in 5

Blood pressure and endovascular therapy, cutbacks in neurology CME, blood test for Alzheimer’s

OCT 19, 20234 MIN

Description

Neurology Today Editor-in-chief Joseph E. Safdieh, MD, FAAN, discusses new research on blood pressure targets for stroke after endovascular therapy, changing policies on CME, and a direct-to-consumer blood test for Alzheimer’s disease.